Subgroup analysis assesses eplontersen's impact on response based on polyneuropathy severity in ATTRv-PN patients, suggesting tailored treatments.
To assess the impact of baseline polyneuropathy severity on eplontersen response, in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
No takes yet. Share an insight, caveat, or question.
Brannagan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: